Inflammatory Skin Disease

Some preliminary evidence supports the use of zinc in the treatment of acne vulgaris and hidradenitis suppurativa, although further studies are necessary to evaluate zinc supplementation in treating inflammatory skin disease, according to a study.

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab, according to researchers in The Lancet.